Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections.
Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA)